Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Sep 27;77(13):1309-12.
doi: 10.1212/WNL.0b013e318230a15a. Epub 2011 Sep 14.

Subclinical multisystem neurologic disease in "pure" OPA1 autosomal dominant optic atrophy

M R Baker  1 , K M Fisher, R G Whittaker, P G Griffiths, P Yu-Wai-Man, P F Chinnery
Affiliations

Subclinical multisystem neurologic disease in "pure" OPA1 autosomal dominant optic atrophy

M R Baker et al. Neurology. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Motor evoked potentials (MEPs) and central motor conduction times (CMCTs)
(A, B) Examples of motor evoked potentials (MEPs) obtained from a patient OA-2 (black trace) with subclinical evidence of abnormal central conduction (central conduction delay) and a representative age-matched control (red trace) matched for height and peripheral motor conduction time (PMCT). (A) Upper limb MEPs recorded from right first dorsal interosseous (FDI). (B) Lower limb MEPs recorded from right extensor digitorum brevis (EDB). MEPs are aligned to the stimulus. Each trace is an average of 20 individual MEPs. Dashed vertical lines indicate MEP onsets. (C, D) Summary MEP data for dominant optic atrophy (DOA) and non-DOA patients (n = 14). Central motor conduction times (CMCTs) are plotted against age and compared with normative data. Each data point represents one patient. Solid horizontal lines show the mean CMCT within the normal population and gray boxes extend 2 standard deviations above and below the mean. (C) Upper limb (FDI) CMCTs. (D) Lower limb (EDB) CMCTs.
See this image and copyright information in PMC

References

    1. Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010;133:771–786 - PMC - PubMed
    1. Marelli C, Amati-Bonneau P, Reynier P, et al. Heterozygous OPA1 mutations in Behr syndrome. Brain Epub 2011 - PubMed
    1. Horvath R, Hudson G, Ferrari G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006;129:1674–1684 - PubMed
    1. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies: disease mechanisms and therapeutic strategies. Prog Retin Eye Res 2011;30:81–114 - PMC - PubMed
    1. Zeviani M. OPA1 mutations and mitochondrial DNA damage: keeping the magic circle in shape. Brain 2008;131:314–317 - PubMed

Publication types

MeSH terms